Background: Autologous hematopoietic cell transplantation (HCT) is being investigated for poor prognosis multiple sclerosis (MS), aiming to achieve disease stabilization. Long-term outcomes, however, have only been reported from small case series. Objective: To evaluate long-term outcomes after HCT for treatment of MS in a large, international retrospective cohort study. Methods: Eligible cases had received autologous HCT for the treatment of MS between 01/1995 and 12/2006 and had a minimum set of data including Expanded Disability Status Score (EDSS) at baseline, subtype of MS at baseline, information on the treatment protocol and at least one follow-up visit/report after HCT. The primary outcomes were MS progression-free survival from time prior to stem cell mobilization and overall survival. The probabilities of progression-free and overall survival were calculated using KaplanMeier survival curves and multivariate analysis was run using a Cox model. Results: Data was collected from 23 centers in 13 countries, for 281 evaluable patients with median follow up of 6.6 years (range 0.2-16 y). The population included 164 women, (58%), overall median age at HCT of 37 years (range 14-65); 46 patients had relapsing remitting (RR) MS (16%), 186 had secondary progressive MS (66%), 32 had primary progressive MS (11%) and 17 had progressive relapsing MS (6%). The median EDSS score prior to mobilization was 6.5 (range 1.5-9.0). Five-year probabilities of progression free and overall survival were 49% (95% confi dence interval [CI], 43-55 %) and 93 % (95% CI, 91-95 %) respectively. Factors aff ecting MS progression were age older than 37 years (HR=1.40, p=0.04), progressive vs. relapsing forms of MS (HR=1.6, p=0.02) and >2 previous line of MS therapy (HR=1.6, p=0.005). There were no diff erences in outcomes related to the source of data (CIBMTR or EBMT). Conclusions: We report the largest study to date describing longterm outcomes in HCT for MS. Although the majority of patients had progressive forms of MS and failed to respond to prior treatment, the results demonstrate that nearly half of the patients survived free from neurological progression for 5 years after HCT. Younger age, RRMS and fewer lines of prior therapy were associated with better outcomes. Earlier transplantation in patients with active infl ammatory disease may further improve MS outcomes. The bone marrow (BM) provides a complex and unique microenvironment that controls the functions of Hematopoietic Stem Cells (HSC), commonly recognized as the stem cell niche. The structural and functional establishment at the embryo stage of this privileged niche critically depends on the developmental process of endochondral ossifi cation. Through a "developmental engineering" approach, the endochondral route was recapitulated using human adult Mesenchymal Stromal Cells (hMSC) seeded on a collagen sponge and cultured in chondrogenic and hypertrophic conditions. Upon implantation into nude C57BL/6 mice, the cartilaginous template underwent extensive remodeling with vessel ingrowth (CD31+), osteoclast activity (TRAP+, MMP9+), and formation of mineralized bony tissue associated with BM thus defi ning an Ectopic Ossicle (EO). FACS analysis of the EO-derived BM displayed comparable frequencies of diff erent cell types to control BM (native femur), including Lin-Sca+Kit+CD34-CD135-CD150+ HSC. Whole BM (CD45.2+) was then transplanted together with competitor BM (CD45.1+) into lethally irradiated congenic mice (CD45.1+CD45.2+). EO-derived HSC engrafted into recipients developing blood chimerism. Analysis of circulating cells at 1, 2, and 3.5 months showed similar relative frequencies of B, T, and myeloid cells among mice that received EO and control BM. After 3.5 months, FACS analysis of explanted femurs confi rmed the presence of HSC of EO origin; additionally, relative frequencies of phenotypically defi ned progenitors (multipotent, megakaryocyte-erythroid, common myeloid /granulocyte-macrophage) confi rmed that whole BM transplantion successfully reconstituted a functional and hierarchically complete hematopoietic compartment. Thus, the engineered EO initially enabled homing of HSC towards the newly remodeled stromal tissue. Engrafted HSC demonstrated long-term proliferative and diff erentiation potential upon transplantion, supporting the hypothesis of a functional equivalence between control and EO-derived BM. The engineering of ectopic BM niches derived from hMSC can serve as a model to investigate physiological and pathological mechanisms(e.g., HSC engraftment and homeostasis, regulatory interactions of malignant cells with the stromal compartment). Moreover, it opens the perspective towards improving critical aspects in HSC-based therapeutics (e.g., harvesting, expansion, delivery). Non-relapse mortality (NRM) is high after mismatched umbilical cord blood (UCB) transplants. An earlier report that showed the importance of matching at the HLA-C locus considered matching at HLA-A, -B, -C at low resolution and HLA-DRB1. Therefore, we examined the eff ect of allele-level matching at HLA-A, -B, -C,-DRB1 in 1568 donor-recipient pairs; 38% had AML, 52% ALL and 10%, MDS. Most patients (77%) were younger than 20 years and transplants occurred in 2000 -2010; median follow-up was 4 years. All transplants used a single UCB unit, myeloablative conditioning regimen and calcineurin inhibitior GVHD prophylaxis. Most donor-recipient pairs were mismatched at two or more alleles. Only 7% of donorrecipient pairs were matched at HLA-A, -B, -C, -DRB1 (8/8); 15% were mismatched at one (7/8), 26% at two (6/8), 30% at three (5/8), 16% at four (4/8) and 5% at fi ve (3/8) alleles. Cox regression models were built to assess the eff ect of donor-recipient HLA-match on mortality. The models considered overall mismatch (8/8 vs. 7/8 vs. 6/8 vs. 5/8 vs. 4/8 vs. 3/8) and at individual HLA-loci. P-values <0.01 were considered signifi cant. The results shown in the Table are adjusted for age, disease, disease status, pre-cryopreserved total nucleated cell dose (TNC), conditioning regimen and transplant period. TNC < 3 x 10 7 /kg was associated with higher NRM and independent of HLA-match. NRM risks were higher after 7/8, 6/8, 5/8, 4/8 and 3/8 HLA-matched transplants compared to 8/8. NRM risks were higher with isolated mismatches at HLA-A (HR 3.05, p=0.002), -C (HR 3.04, p=0.01) or -DRB1 (HR 2.93, p=0.005) but not when the mismatch occurred at HLA-B (HR 1.26, p=0.72). Despite higher NRM risks, diff erences in overall mortality risks did not reach statistical significance except for 3/8 HLA-matched transplants. These data support the selection algorithm for single UCB units to include a minimum TNC of 3 x 10 7 /kg and allele-level HLA-match at HLA-A, -B, -C and DRB1. Only 54% of units matched at HLA-A, -B, -DRB1 were also matched at HLA-C and for units with a single mismatch at HLA-A, -B or DRB1, only 25% were matched at HLA-C. In the absence of a fully matched unit, mismatches at 1 -4 alleles are acceptable. Increasing the UCB unit TNC to >5 x 10 7 /kg did not lower mortality confi rming HLA-match is an important predictor of mortality. High NRM and overall mortality risks after transplants mismatched at 5 alleles suggest avoiding this degree of HLA disparity.
Background: Autologous hematopoietic cell transplantation (HCT) is being investigated for poor prognosis multiple sclerosis (MS), aiming to achieve disease stabilization. Long-term outcomes, however, have only been reported from small case series. Objective: To evaluate long-term outcomes after HCT for treatment of MS in a large, international retrospective cohort study. Methods: Eligible cases had received autologous HCT for the treatment of MS between 01/1995 and 12/2006 and had a minimum set of data including Expanded Disability Status Score (EDSS) at baseline, subtype of MS at baseline, information on the treatment protocol and at least one follow-up visit/report after HCT. The primary outcomes were MS progression-free survival from time prior to stem cell mobilization and overall survival. The probabilities of progression-free and overall survival were calculated using KaplanMeier survival curves and multivariate analysis was run using a Cox model. Results: Data was collected from 23 centers in 13 countries, for 281 evaluable patients with median follow up of 6.6 years (range 0.2-16 y). The population included 164 women, (58%), overall median age at HCT of 37 years (range 14-65); 46 patients had relapsing remitting (RR) MS (16%), 186 had secondary progressive MS (66%), 32 had primary progressive MS (11%) and 17 had progressive relapsing MS (6%). The median EDSS score prior to mobilization was 6.5 (range 1.5-9.0). Five-year probabilities of progression free and overall survival were 49% (95% confi dence interval [CI] , 43-55 %) and 93 % (95% CI, 91-95 %) respectively. Factors aff ecting MS progression were age older than 37 years (HR=1.40, p=0.04), progressive vs. relapsing forms of MS (HR=1.6, p=0.02) and >2 previous line of MS therapy (HR=1.6, p=0.005). There were no diff erences in outcomes related to the source of data (CIBMTR or EBMT). Conclusions: We report the largest study to date describing longterm outcomes in HCT for MS. Although the majority of patients had progressive forms of MS and failed to respond to prior treatment, the results demonstrate that nearly half of the patients survived free from neurological progression for 5 years after HCT. Younger age, RRMS and fewer lines of prior therapy were associated with better outcomes. Earlier transplantation in patients with active infl ammatory disease may further improve MS outcomes. The bone marrow (BM) provides a complex and unique microenvironment that controls the functions of Hematopoietic Stem Cells (HSC), commonly recognized as the stem cell niche. The structural and functional establishment at the embryo stage of this privileged niche critically depends on the developmental process of endochondral ossifi cation. Through a "developmental engineering" approach, the endochondral route was recapitulated using human adult Mesenchymal Stromal Cells (hMSC) seeded on a collagen sponge and cultured in chondrogenic and hypertrophic conditions. Upon implantation into nude C57BL/6 mice, the cartilaginous template underwent extensive remodeling with vessel ingrowth (CD31+), osteoclast activity (TRAP+, MMP9+), and formation of mineralized bony tissue associated with BM thus defi ning an Ectopic Ossicle (EO). FACS analysis of the EO-derived BM displayed comparable frequencies of diff erent cell types to control BM (native femur), including Lin-Sca+Kit+CD34-CD135-CD150+ HSC. Whole BM (CD45.2+) was then transplanted together with competitor BM (CD45.1+) into lethally irradiated congenic mice (CD45.1+CD45.2+). EO-derived HSC engrafted into recipients developing blood chimerism. Analysis of circulating cells at 1, 2, and 3.5 months showed similar relative frequencies of B, T, and myeloid cells among mice that received EO and control BM. After 3.5 months, FACS analysis of explanted femurs confi rmed the presence of HSC of EO origin; additionally, relative frequencies of phenotypically defi ned progenitors (multipotent, megakaryocyte-erythroid, common myeloid /granulocyte-macrophage) confi rmed that whole BM transplantion successfully reconstituted a functional and hierarchically complete hematopoietic compartment. Thus, the engineered EO initially enabled homing of HSC towards the newly remodeled stromal tissue. Engrafted HSC demonstrated long-term proliferative and diff erentiation potential upon transplantion, supporting the hypothesis of a functional equivalence between control and EO-derived BM. The engineering of ectopic BM niches derived from hMSC can serve as a model to investigate physiological and pathological mechanisms(e.g., HSC engraftment and homeostasis, regulatory interactions of malignant cells with the stromal compartment). Moreover, it opens the perspective towards improving critical aspects in HSC-based therapeutics (e.g., harvesting, expansion, delivery).
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Presidential Symposium O92 Is allele-level HLA-matching relevant for single umbilical cord blood transplants? M. Eapen, J. Klein, A. Ruggeri, S. Spellman, W. Arcese, L. Baxter-Lowe, M. Fernandez-Vina, M. Horowitz, S. Lee, F. Locatelli, A. Paolo Lori, S. Marino, G. Michel, G. Sanz, E. Gluckman, V. Rocha Non-relapse mortality (NRM) is high after mismatched umbilical cord blood (UCB) transplants. An earlier report that showed the importance of matching at the HLA-C locus considered matching at HLA-A, -B, -C at low resolution and HLA-DRB1. Therefore, we examined the eff ect of allele-level matching at HLA-A, -B, -C,-DRB1 in 1568 donor-recipient pairs; 38% had AML, 52% ALL and 10%, MDS. Most patients (77%) were younger than 20 years and transplants occurred in 2000 -2010; median follow-up was 4 years. All transplants used a single UCB unit, myeloablative conditioning regimen and calcineurin inhibitior GVHD prophylaxis. Most donor-recipient pairs were mismatched at two or more alleles. Only 7% of donorrecipient pairs were matched at HLA-A, -B, -C, -DRB1 (8/8); 15% were mismatched at one (7/8), 26% at two (6/8), 30% at three (5/8), 16% at four (4/8) and 5% at fi ve (3/8) alleles. Cox regression models were built to assess the eff ect of donor-recipient HLA-match on mortality. The models considered overall mismatch (8/8 vs. 7/8 vs. 6/8 vs. 5/8 vs. 4/8 vs. 3/8) and at individual HLA-loci. P-values <0.01 were considered signifi cant. The results shown in the Table are adjusted for age, disease, disease status, pre-cryopreserved total nucleated cell dose (TNC), conditioning regimen and transplant period. TNC < 3 x 10 7 /kg was associated with higher NRM and independent of HLA-match. NRM risks were higher after 7/8, 6/8, 5/8, 4/8 and 3/8 HLA-matched transplants compared to 8/8. NRM risks were higher with isolated mismatches at HLA-A (HR 3.05, p=0.002), -C (HR 3.04, p=0.01) or -DRB1 (HR 2.93, p=0.005) but not when the mismatch occurred at HLA-B (HR 1.26, p=0.72). Despite higher NRM risks, diff erences in overall mortality risks did not reach statistical significance except for 3/8 HLA-matched transplants. These data support the selection algorithm for single UCB units to include a minimum TNC of 3 x 10 7 /kg and allele-level HLA-match at HLA-A, -B, -C and DRB1. Only 54% of units matched at HLA-A, -B, -DRB1 were also matched at HLA-C and for units with a single mismatch at HLA-A, -B or DRB1, only 25% were matched at HLA-C. In the absence of a fully matched unit, mismatches at 1 -4 alleles are acceptable. Increasing the UCB unit TNC to >5 x 10 7 /kg did not lower mortality confi rming HLA-match is an important predictor of mortality. High NRM and overall mortality risks after transplants mismatched at 5 alleles suggest avoiding this degree of HLA disparity.
O93
Tyrosine kinase inhibitors (TKIs) improve outcome of allogeneic haematopoietic stem cell transplantation (allo-HCST) for Philadelphia chromosome acute lymphoblastic leukaemia (Ph+ALL) in fi rst complete remission (CR1): a study from the ALWP of EBMT E. Brissot, M. Labopin, M. Beckers, G. Socie, L. Volin, A. Rambaldi, J. Finke, S. Lenhoff , N. Kröger, G. Ossenkopple, C. Craddock, I. YakoubAgha, G. Gurman, N. Russell, V. Koza, J. Cornelissen, J. Esteve, M 
. Mohty on behalf of the Acute Leukemia Working Party of EBMT
The introduction of TKIs with activity against ABL protein has likely modifi ed the natural history of Ph+ALL. Indeed, TKIs used pre and post-allo-HSCT may allow for improved outcome. However, data are still scarce in this fi eld. The current study aimed to assess outcomes in a cohort of 473 Ph+ALL patients who received allo-HSCT in CR1 between 2000-2010 and focused on the role of TKIs in this setting. In this series, median age was 42 (range 18-70) and 55% were males. Median time from diagnosis to CR1 was 44 days and from diagnosis to allo-HSCT 158 days. 225 patients (47.4%) received allo-HSCT from an HLA-identical sibling, while 249 (52.6%) received an HLA-matched unrelated graft. 79% patients underwent a myeloablative conditioning (MAC) regimen and 21% underwent a reduced intensity conditioning (RIC) regimen. 329 patients received a TKI at time of induction therapy-mainly imatinib (90%)-and 157 patients received TKI in the post transplant period. The overall incidences of acute GVHD and chronic GVHD (cGVHD) were 40% and 53% respectively. At 3 years, OS and LFS were 53% and 42%. The RI was 35% and NRM 23%. In multivariate analysis, 2 predictive factors were associated with LFS: TKI use during induction therapy improved LFS (P=0.03 HR=0.76,95%CI,0.59-0.97) while age>42y was associated with lower LFS (P=0.02 HR=1.01,95%CI,1.01-1.02). In multivariate analysis for relapse, 2 factors were associated with decreased relapse: use of TKI in pre-allograft treatment (P=0.04 HR=0.71,95%CI,0.52-0.98) and use of an unrelated donor (UD) vs. identical sibling (p=0.001,HR=0.6,95%CI,0.44-0.81). Also, a RIC regimen was associated with an increased incidence of relapse (p=0.007 HR=1.64,95%CI,1.14-2.35). Concerning NRM, age>42 and UD were factors associated with higher NRM (P=0.02, HR=.02, 95%CI, 1.01-1.03;P=0.0 HR=1.46,95%CI,1.01-2.12), while a RIC regimen was the only factor associated with lower NRM (P=0.02 HR=0.51,95%CI=0.3-0.89). Concerning the incidence of cGVHD, PBSC vs BM was the only risk factor of developing a cGVHD (p=0.005 HR=1.63,95%CI=1.16-2.28). Interestingly, post-transplant TKI was a protective factor of cGVHD development (p=0.006 HR=0.64 95%CI=0.47-0.88).
Overall, this large study demonstrated that the introduction of TKIs in Ph+ALL treatment paradigm (pre and post transplant) allowed for a signifi cant outcome improvement after allo-HSCT including LFS, relapse, but also incidence of cGVHD, suggesting that further prospective studies are needed to refi ne the use of TKIs after allo-HSCT.
O94
Results from a prospective, multicentre registry of mechanical ventilation in children after allogeneic haematopoietic stem cell transplantation S. van Gestel (1) Introduction: Exact data on prognosis and best therapy of children requiring mechanical ventilation (MV) after haematopoietic stem cell transplantation (HSCT) is lacking, since all previous studies were retrospective in design, and nearly all were single centre. In January 2009, we started a multicenter, international registry to prospectively assess outcome of these children. Objectives: First, to prospectively describe epidemiology and outcome of MV in children after allogeneic HSCT and second, to assess factors associated with mortality in intubated children.
Design: The registry started in January 2009 with ongoing inclusion since then. Four European HSCT centres and their affi liated paediatric intensive care units (PICUs) participate. These centres encompass two national cohorts (Czech Republic (Prague) and the Netherlands (Leiden, Utrecht)). The participating centre from Paris is one of the largest paediatric HSCT centres in France. All children who receive noninvasive or endotracheal MV are included. Demographic data, transplantation details, PICU treatment details and PICU outcome are recorded. Results: In January 2012, there were 86 patients included. The fl ow chart of inclusions is presented in Figure 1 . There was a signifi cant diff erence between the four centres in severity of illness on admission to PICU (p=0.028), in the proportion of children who were intubated after HSCT (p=0.002) and in PICU mortality rates (p=0.05). PICU treatment varied in the application of noninvasive ventilation (10%-80% of admissions), renal replacement therapy (3%-60% of admissions) and high frequency ventilation (8%-46% of admissions). Table 1 displays outcome and treatment data for each centre separately. Overall, 33 of the 62 admissions who received endotracheal MV ended in death in PICU (case fatality rate 53%). In multiple regression analysis, the presence of severe pulmonary problems (defi ned as an oxygenation index above 15) on day three of PICU admission was the only signifi cant association with mortality (p = 0.005, odds ratio 7.4, 95% confi dence interval 1.8-30.0). Conclusion: Within the overall PICU population, children after HSCT have the highest mortality rates: 53% of patients who were intubated died in PICU. There were signifi cant diff erences between centres in the proportion of admissions for, the approach to and the outcome of MV in children after HSCT. We strongly plea for a larger (European) registry to optimise treatment in this fragile population.
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Reduced intensity transplant improves survival in intermediate risk AML >40 years if a sibling donor is used with no additional benefi t for myeloablative conditioning: analysis of 277 transplants in the UK NCRI AML15 Trial compared to chemotherapy N. Russell, R. Hills, L. Kjeldsen, J. Yin, C. Craddock, A. Burnett 
for the NCRI AML WG
RIC off ers a feasible option for older patients but the clinical benefi t in AML is unclear. We have examined the impact of RIC in CR1 on the outcome of patients aged 40-60 yrs treated within the AML15 trial compared to chemotherapy and to MAC transplant. Patients and Methods: AML15 off ered the option of RIC or MAC transplant for patients not good risk aged 40+yrs. Excluding good risk patients, a total of 1672 patients 40-60 years were randomised, of whom 1389 entered CR, and 394 were transplanted (112 MAC, 269 RIC, 13 others). Median follow up for survival is 67 months. Outcomes following transplant are compared using the logrank test, with transplant versus not analysed using Mantel-Byar methods to allow for time to transplant. Results: For RIC, NRM was 13% at 5 years with sibling donors but was signifi cantly higher with MUD (34% p<0.0001). For MAC the fi gures were 28% and 22% for sibling and MUD (p=1.0). Relapse risk was signifi cantly reduced by RIC transplant and was similar irrespective of donor type (sibling/MUD) or cytogenetic group. There was no signifi cant diff erence in the rates of relapse between MAC and RIC in either intermediate or adverse risk disease. The survival for the 269 patients undergoing RIC was signifi cantly superior to no transplant (52% v 42%, HR 0.83 (0.69-0.99), p=0.04). There was clear benefi t in the 173 intermediate risk group (58% v 46%, HR 0.72 (0.57-0.91) p=0.004) with less evidence for the 40 who had adverse risk (16% v 10%, HR 0.89 (0.59-1.35) p=0.6). Considering the donor the survival benefi t was restricted to sibling RIC, 61% v MUD 35% v no transplant 41%) however the MUD group were worse risk, making comparison diffi cult. In analysis by cytogenetics, sibling RIC gave consistently better survival. In analyses adjusted for age, cytogenetics, WCC, donor and secondary disease, survival from transplant was not signifi cantly diff erent between RIC and MAC (HR 1.15 (0.69-1.91) p=0.6). Conclusion: This analysis shows that RIC is associated with a potent GvL eff ect and improves the survival of older patients with AML but possibly only if a sibling donor is used. There was less benefi t of RIC for adverse risk. However, given the lack of statistical heterogeneity, our data does not exclude a benefi t for patients with adverse risk or for those undergoing MUD. Comparison of RIC with MAC is confounded by selection bias and that RIC were performed in older patients but there appears no advantage in choosing MAC in this age group.
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Tracking haematopoietic system dynamics in humans by retroviral tagging Rome "Tor Vergata" (Milan, IT) The study of hematopoietic composition and stem cells (HSC) dynamics in humans relies on data derived from in vitro experiments or animal models, but direct evidences on clonal tracking in humans are currently missing. Upon retroviral gene transfer, transduced cells are univocally marked by vector integration sites (IS). Gene therapy (GT) clinical trials for ADA (adenosine deaminase) defi cient-SCID and Wiskott-Aldrich Syndrome (WAS) are based on the infusion of genetically engineered HSC. In these patients the progeny of vector marked cells is traceable in vivo by IS analysis, allowing to follow individual engrafted HSC clones. To date, we collected a total of 23.156 IS from 3 WAS patients treated with lentiviral vector GT up to 1 year and 4.845 IS from 4 ADA-SCID patients treated with retroviral GT up to 6 years after treatment. We detected in WAS patients an increase in the diversity of clonal repertoires during the fi rst 12 months after GT and the presence of self-limiting waves of hematopoietic output from transduced HSC early after transplant. No aberrant clonal expansion was observed. Multipotent HSC could be tracked overtime by detecting identical IS in HSC/colony forming units and mature cells. We also exploited statistical estimators, to determine the approximate size of the HSC pool active in our patients. In ADA-SCID patients we showed that identical IS are consistently detected at multiple lineages level even several years after GT, providing the fi rst evidence that in vitro stimulated HSC retain long-term activity in humans. By semi-quantitative PCRs we tracked the dynamics and activity of specifi c HSC clones over a period of 5 years. We also analyzed IS in sorted T cell subtypes from ADA-SCID GT patients receiving infusions of gene corrected mature lymphocytes. Strikingly, we found that transduced T cells with an apparent naïve phenotype retained their plasticity, as they share the highest number of IS with other T subpopulations, while still surviving in vivo 10 years after infusion. We found that we are actually tracking the fate of recently defi ned T memory stem cells (TSCM) carrying naïve plasticity and memory survival. We have evidences that TSCM could have been generated upon in vitro stimulation used for lymphocytes transduction. In summary, our IS studies allow defi ning crucial HSC and TSCM properties in vivo in humans providing new information with profound impact on the design of therapeutic strategies for hematological diseases.
O97
Modelling novel conditioning strategies using a Zebrafi sh transplant model
)Carl Carus University Hospital Dresden (Dresden, DE); (2)Center of Regenerative Therapies Dresden -CRTD (Dresden, DE)
Objectives: Successful hematopoietic cell transplantation (HCT) is determined by factors aff ecting engraftment of donor hematopoietic stem/progenitor cells (HSPC). To achieve engraftment, traditional approaches have relied on the use of unspecifi c toxic conditioning therapies including irradiation (TBI) and/or chemotherapy. We aimed at developing less invasive approaches to allografting in a zebrafi sh transplant model by employing immunosuppressive and stem cell niche targeted strategies. As in mammals, SDF-1 promotes HSPC mobilization and migration in zebrafi sh. In murine models it has been demonstrated that the S1P1 agonist SEW2871 (SEW) increases AMD3100 (AMD) induced HSPC mobilization. We hypothesized that release of host HSPC from the niche during conditioning would allow for lower doses of TBI. Methods: Pre-HCT conditioning regimen of the recipients included retro-orbital injection of AMD and delivery of SEW and Cyclosporine S5 A (CSA) via fi sh water followed by TBI. GFP labeled HSPC from transgenic donors were administrated retro-orbitally at day 0. Chimerism was quantifi ed at day +28 by FACS of the GFP+ cells in the recipients HSPC fraction. Results: To determine the minimal TBI dose enabling for a stable and relevant engraftment we injected 500.000 (500k) unfractionated HSPC from transgene animals into hosts irradiated with various doses. The minimal TBI dose allowing partial engraftment in a relevant proportion of animals was determined at 15 Gy (d -1). Lower doses of irradiation were not suffi cient to overcome the allogeneic barrier (Fig. 1) . Limiting dilution analyses (100K-500K cells) revealed 300K HSPC providing the best survival and engraftment rate analyzed 28 days post HCT. Addition of CSA (d -2 to +10) was associated with a signifi cantly improved survival (median survival 27 days vs. not reached after 2 months post HCT) and engraftment (P< 0.05). Administration of AMD and SEW (d -4 to d -2) lead to a higher engraftment level after a TBI dose of 10Gy (Fig. 2) . AMD and SEW demonstrated to be eff ective only as combination and not alone. Conclusion: Our data indicate that immunosuppressive drugs already in use in the clinic also enhance the engraftment and survival in the zebrafi sh transplant model. The combined administration of AMD and SEW before transplantation increases the effi cacy of allografting. The described technology may be useful to test further compounds for their additive or synergistic eff ects together with minimal conditioning therapy.
